Denosumab in postmenopausal women with low bone mineral density.
Rifkin
William D
WD
D019386:Alendronate / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D000069448:Denosumab; D032984:Ethics, Research; D005260:Female; D050723:Fractures, Bone; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010919:Placebos / Q000627:therapeutic use*; D053245:RANK Ligand; D012107:Research Design; D012306:Risk
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D010919:Placebos; D053245:RANK Ligand; D000069448:Denosumab; D019386:Alendronate